Literature DB >> 22974093

Data quality at the Icelandic Cancer Registry: comparability, validity, timeliness and completeness.

Lara Gudrun Sigurdardottir1, Jon Gunnlaugur Jonasson, Sigrun Stefansdottir, Anna Jonsdottir, Gudridur Helga Olafsdottir, Elinborg Jona Olafsdottir, Laufey Tryggvadottir.   

Abstract

INTRODUCTION: The nationwide Icelandic Cancer Registry (ICR) was established in 1954 and has been extensively used for research from the outset although formal quality assessment of the registry database has not previously been undertaken. In this paper we report the first formal evaluation of the comparability, validity, timeliness and completeness of the ICR.
MATERIAL AND METHODS: Data from the ICR for the period 1955-2009 (41 994 cancer diagnoses) were used, applying established quantitative and semi-quantitative methods. In order to evaluate the completeness of the ICR, record linkage was performed between the ICR and the population-based Hospital Discharge Registry to identify potential missing cases for tumour diagnoses in 2000 and 2001.
RESULTS: The registration is in accordance with internationally accepted standards. It has high validity, but random variation in rates is prominent in this small population. Record linkage with the Hospital Discharge Registry revealed that in addition to the 2459 cancers registered in 2000-2001, 21 cases were missing, indicating 99.15% completeness. Tumours of the central nervous system constituted 71%, and haematological malignancies 19% of these missing entries. DISCUSSION: The ICR has high completeness, validity and timeliness and is comparable to the cancer registries of the other Nordic Countries. As cancer registries have many important roles, it is of great importance that their data are at all times as complete and valid as possible. Thus the ICR aims to constantly improve and update the data gathering process.

Entities:  

Mesh:

Year:  2012        PMID: 22974093     DOI: 10.3109/0284186X.2012.698751

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  41 in total

1.  Pre-diagnostic 25-hydroxyvitamin D levels and survival in cancer patients.

Authors:  Johanna E Torfadottir; Thor Aspelund; Unnur A Valdimarsdottir; Mary Frances Cotch; Laufey Tryggvadottir; Tamara B Harris; Vilmundur Gudnason; Hans-Olov Adami; Lorelei A Mucci; Edward L Giovannucci; Meir J Stampfer; Laufey Steingrimsdottir
Journal:  Cancer Causes Control       Date:  2019-02-25       Impact factor: 2.506

2.  Neurologic disorders in 4858 survivors of central nervous system tumors in childhood-an Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study.

Authors:  Line Kenborg; Jeanette Falck Winther; Karen Markussen Linnet; Anja Krøyer; Vanna Albieri; Anna Sällfors Holmqvist; Laufey Tryggvadottir; Laura Maria Madanat-Harjuoja; Marilyn Stovall; Henrik Hasle; Jørgen H Olsen
Journal:  Neuro Oncol       Date:  2019-01-01       Impact factor: 12.300

3.  Sleep disruption among older men and risk of prostate cancer.

Authors:  Lara G Sigurdardottir; Unnur A Valdimarsdottir; Lorelei A Mucci; Katja Fall; Jennifer R Rider; Eva Schernhammer; Charles A Czeisler; Lenore Launer; Tamara Harris; Meir J Stampfer; Vilmundur Gudnason; Steven W Lockley
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-05       Impact factor: 4.254

4.  Body fat distribution on computed tomography imaging and prostate cancer risk and mortality in the AGES-Reykjavik study.

Authors:  Barbra A Dickerman; Johanna E Torfadottir; Unnur A Valdimarsdottir; Edward Giovannucci; Kathryn M Wilson; Thor Aspelund; Laufey Tryggvadottir; Lara G Sigurdardottir; Tamara B Harris; Lenore J Launer; Vilmundur Gudnason; Sarah C Markt; Lorelei A Mucci
Journal:  Cancer       Date:  2019-06-10       Impact factor: 6.860

5.  Electronically ascertained extended pedigrees in breast cancer genetic counseling.

Authors:  V Stefansdottir; H Skirton; O Th Johannsson; H Olafsdottir; G H Olafsdottir; L Tryggvadottir; J J Jonsson
Journal:  Fam Cancer       Date:  2019-04       Impact factor: 2.375

6.  New basal cell carcinoma susceptibility loci.

Authors:  Simon N Stacey; Hannes Helgason; Sigurjon A Gudjonsson; Gudmar Thorleifsson; Florian Zink; Asgeir Sigurdsson; Birte Kehr; Julius Gudmundsson; Patrick Sulem; Bardur Sigurgeirsson; Kristrun R Benediktsdottir; Kristin Thorisdottir; Rafn Ragnarsson; Victoria Fuentelsaz; Cristina Corredera; Yolanda Gilaberte; Matilde Grasa; Dolores Planelles; Onofre Sanmartin; Peter Rudnai; Eugene Gurzau; Kvetoslava Koppova; Bjørn A Nexø; Anne Tjønneland; Kim Overvad; Jon G Jonasson; Laufey Tryggvadottir; Hrefna Johannsdottir; Anna M Kristinsdottir; Hreinn Stefansson; Gisli Masson; Olafur T Magnusson; Bjarni V Halldorsson; Augustine Kong; Thorunn Rafnar; Unnur Thorsteinsdottir; Ulla Vogel; Rajiv Kumar; Eduardo Nagore; José I Mayordomo; Daniel F Gudbjartsson; Jon H Olafsson; Kari Stefansson
Journal:  Nat Commun       Date:  2015-04-09       Impact factor: 14.919

7.  Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study.

Authors:  Marianna Thordardottir; Ebba K Lindqvist; Sigrun H Lund; Rene Costello; Debra Burton; Neha Korde; Sham Mailankody; Gudny Eiriksdottir; Lenore J Launer; Vilmundur Gudnason; Tamara B Harris; Ola Landgren; Sigurdur Y Kristinsson
Journal:  Blood Adv       Date:  2017-11-01

8.  Risk of Esophageal Adenocarcinoma After Antireflux Surgery in Patients With Gastroesophageal Reflux Disease in the Nordic Countries.

Authors:  John Maret-Ouda; Karl Wahlin; Miia Artama; Nele Brusselaers; Martti Färkkilä; Elsebeth Lynge; Fredrik Mattsson; Eero Pukkala; Pål Romundstad; Laufey Tryggvadóttir; My von Euler-Chelpin; Jesper Lagergren
Journal:  JAMA Oncol       Date:  2018-11-01       Impact factor: 31.777

9.  Midlife metabolic factors and prostate cancer risk in later life.

Authors:  Barbra A Dickerman; Johanna E Torfadottir; Unnur A Valdimarsdottir; Kathryn M Wilson; Laufey Steingrimsdottir; Thor Aspelund; Julie L Batista; Katja Fall; Edward Giovannucci; Lara G Sigurdardottir; Laufey Tryggvadottir; Vilmundur Gudnason; Sarah C Markt; Lorelei A Mucci
Journal:  Int J Cancer       Date:  2017-11-16       Impact factor: 7.396

10.  Association of BRCA2 K3326* With Small Cell Lung Cancer and Squamous Cell Cancer of the Skin.

Authors:  Thorunn Rafnar; Gudbjorg R Sigurjonsdottir; Simon N Stacey; Gisli Halldorsson; Patrick Sulem; Luba M Pardo; Hannes Helgason; Stefan T Sigurdsson; Thorkell Gudjonsson; Laufey Tryggvadottir; Gudridur H Olafsdottir; Jon G Jonasson; Kristin Alexiusdottir; Asgeir Sigurdsson; Julius Gudmundsson; Jona Saemundsdottir; Jon K Sigurdsson; Hrefna Johannsdottir; Andre Uitterlinden; Sita H Vermeulen; Tessel E Galesloot; Dawn C Allain; Martin Lacko; Bardur Sigurgeirsson; Kristin Thorisdottir; Oskar T Johannsson; Fridbjorn Sigurdsson; Gunnar B Ragnarsson; Helgi Isaksson; Hronn Hardardottir; Tomas Gudbjartsson; Daniel F Gudbjartsson; Gisli Masson; Lambertus A M L Kiemeney; Amanda Ewart Toland; Tamar Nijsten; Wilbert H M Peters; Jon H Olafsson; Steinn Jonsson; Unnur Thorsteinsdottir; Gudmar Thorleifsson; Kari Stefansson
Journal:  J Natl Cancer Inst       Date:  2018-09-01       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.